Headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Henry Schein earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.5450487892727 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern’s rankings:
- Stock Traders Buy High Volume of Put Options on Henry Schein (HSIC) (americanbankingnews.com)
- INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against Henry Schein, Inc. (finance.yahoo.com)
- SHAREHOLDER ALERT: Pawar Law Group Announces Investigation of Securities Claims Against Henry Schein, Inc. – HSIC (finance.yahoo.com)
- Henry Schein (HSIC) Earns Neutral Rating from Analysts at JPMorgan Chase & Co. (americanbankingnews.com)
- Why the 2 Main Dental Supply Companies Just Tanked (fool.com)
HSIC has been the topic of several research reports. Morgan Stanley lowered Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a research note on Wednesday, December 6th. Piper Jaffray Companies restated a “buy” rating and issued a $78.00 target price on shares of Henry Schein in a research note on Wednesday, December 27th. Craig Hallum upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Credit Suisse Group restated a “neutral” rating and issued a $80.00 target price (down from $87.50) on shares of Henry Schein in a research note on Tuesday, November 28th. Finally, Zacks Investment Research upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $83.71.
In related news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/02/18/henry-schein-hsic-earns-daily-coverage-optimism-score-of-0-15.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.